The study is titled “INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold for Safety and Neurologic Recovery in Subjects With Complete Thoracic AIS A Spinal Cord Injury.” Here are five key notes:
1. The study is currently approved to enroll up to 12 patients. However, the company expects the FDA to approve a full 20 patients following completed six-month data review for the first five patients.
2. InVivo plans to submit the six-month data for the first five patients in the second quarter of this year.
3. The study tests the biodegradable Neuro-Spinal Scaffold surgically implanted at the epicenter of the wound designed to act as a physical substrate for nerve sprouting. A preclinical model for spinal cord contusion injury shows spare spinal cord tissue appositional healing, decreased post-traumatic cyst formation and decreased spinal cord tissue pressure.
4. The trial received a Humanitarian Use Device designation and is currently being studied as an Investigational Device Exemption study to treat patients with complete AIS A traumatic acute spinal cord injury.
5. The fifth patient was enrolled in September and previous patients have shown improvement.
More articles on spine surgery:
Dr. Charles Court performs 1st spinal fusion with SpineGuard DSG technology
Cardinal Spine files form D for $.25M in financing: 4 things to know
Stryker, SeaSpine, ChoiceSpine & more—13 key notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
